Measurement of chemotherapy-induced alopecia—time to change
- 611 Downloads
Data on chemotherapy-induced alopecia (CIA) as a side effect of cancer treatment are scarce. CIA is given minimal attention in clinical trials and in the literature. However, when asking the patients with cancer for their opinion, CIA appears to have a major impact, particularly on body image and quality of life. Currently, there is no commonly used measure to evaluate CIA; It is time to improve the management and measurement of CIA.
KeywordsAlopecia Chemotherapy Side effect Data quality
Conflict of interest
All authors declare to have no conflict of interest.
- 2.World Health Organisation (1979) Handbook for reporting results of cancer treatment, vol 48. WHO Offset Publ, GenevaGoogle Scholar
- 3.Institute NC (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).
- 6.Peerbooms M, Breed WPM, van den Hurk CJG (2015 (accepted for publication)) Familiarity, opinions, experiences and knowledge about scalp cooling—a Dutch survey among breast cancer patients and oncological professionals. Asia-Pacific J Oncol NursingGoogle Scholar
- 7.Hurk van den CJG (2013) Safety and effectiveness of scalp cooling in cancer patients undergoing cytotoxic treatment. Thesis. Leiden University Medical Center. LeidenGoogle Scholar
- 11.Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R (2001) Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol 19(8):2213–2221PubMedGoogle Scholar
- 12.Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T (2005) Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 23(7):1401–1408CrossRefPubMedGoogle Scholar
- 13.Brufman G, Colajori E, Ghilezan N, Lassus M, Martoni A, Perevodchikova N, Tosello C, Viaro D, Zielinski C (1997) Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 8(2):155–162Google Scholar
- 15.Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, Guillot B, Romieu G, Bessis D (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879–2884CrossRefPubMedGoogle Scholar